What is Cytogel Pharma?
Cytogel Pharma operates as a specialized clinical-stage biopharmaceutical entity dedicated to the advancement of novel endomorphin-based peptide therapies. The company's core mission centers on the development of CYT-1010, a lead drug candidate engineered to address the critical limitations of current pain management protocols. By targeting specific pain pathways, Cytogel Pharma aims to deliver effective relief for moderate to severe conditions while mitigating the risks of addiction and respiratory depression commonly associated with traditional opioid-based treatments. This focus on safer, first-in-class alternatives positions the firm as a pivotal player in the evolving field of non-addictive pain therapeutics, bridging the gap between scientific innovation and clinical necessity.
How much funding has Cytogel Pharma raised?
Cytogel Pharma has raised a total of $5.6M across 3 funding rounds:
Private Equity
$2.2M
Debt
$750K
Private Equity
$2.7M
Private Equity (2010): $2.2M, investors not publicly disclosed
Debt (2013): $750K, investors not publicly disclosed
Private Equity (2015): $2.7M, investors not publicly disclosed
Key Investors in Cytogel Pharma
Undisclosed Investor
An institutional investment firm specializing in long-term capital deployment for high-growth clinical-stage biopharmaceutical ventures.
Undisclosed Investor
A specialized credit provider focused on supporting the operational and research requirements of innovative healthcare and life sciences companies.
Undisclosed Investor
A strategic investment partner with a focus on early-to-mid stage drug development and therapeutic platform technologies.
What's next for Cytogel Pharma?
With the recent influx of capital, Cytogel Pharma is well-positioned to accelerate its clinical trial milestones and expand its research infrastructure. The strategic roadmap likely involves advancing CYT-1010 through rigorous regulatory phases to establish definitive proof of concept. As the company scales its operations, the focus will remain on validating the safety and efficacy profiles of its peptide candidates, potentially setting the stage for future commercialization or strategic partnerships with larger pharmaceutical conglomerates. The firm's ability to maintain its momentum in the development of non-addictive pain solutions will be a key indicator of its long-term viability and potential to disrupt the multi-billion dollar pain management market.
See full Cytogel Pharma company page
